Testing RO7830698 in Healthy Adults and Adults With Chronic Obstructive Pulmonary Disease
Tests how safe RO7830698 is in healthy adults and adults with COPD.
Plain-language title generated from the registry record
Registry title: A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Wythenshawe, United KingdomSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07822334, who can take part
Where in United Kingdom
- Medicines Evaluation UnitWythenshawe, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07822334
- Record updated
- 20 October 2026
- Original description
This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive pulmonary disease (COPD).Read full original descriptionShow less
A Phase I, Randomized, Investigator and Participant-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of RO7830698 in Healthy Participants (Part 1) and in Participants With Chronic Obstructive Pulmonary Disease (Part 2)
This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive pulmonary disease (COPD).
Inclusion: All participants:; Body mass index (BMI) between 18 and 32 kilograms per meter square (kg/m2); Agreement to adhere to the contraception requirements; Part 1:; Absence of evidence of any active or chronic disease; Part 2:; Confirmed diagnosis of COPD for > 6 months, as defined by the Global Initiative for Chronic obstructive Lung Disease (GOLD) guidelines; Using maintenance inhaled therapy that may include inhaled corticosteroids (ICS) and/or long-acting β-agonist (LABA) and/or long-acting muscarinic antagonist (LAMA) as separate inhaler(s) or in combination preparation(s); Current smoker or ex-smoker with a tobacco history of >= 10 pack years.
Exclusion: Treatment with medications targeting the same pathways as RO7830698, immunomodulatory/ immunosuppressive therapy, or licensed biologics for COPD and asthma within protocol-defined periods; Participation in any clinical study of a drug or medical device within protocol-defined periods; Current or chronic history of clinically significant liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert syndrome or asymptomatic gallstones) or cirrhosis; Known history of allergy to drugs or other substances, or clinically significant, acute, and/or uncontrolled allergic disease; Known or suspected history of immunosuppression; History of recurrent severe infections and underlying conditions predisposing participant to infections; History of disseminated herpes simplex infection, or recurrent (> 1 episode) or disseminated herpes zoster; Autoimmune disease requiring systemic immunosuppressive therapy; History of or presence of any clinically significant unstable cardiovascular disease; Positive results for hepatitis B infection, human immunodeficiency virus infection, or hepatitis C infection at the Screening visit; Evidence of tuberculosis infection or disease; Any other conditions that may affect providing informed consent or study protocol adherence, or if study participation may affect study results or participant safety; Pregnant or breastfeeding, or planning to become pregnant during the study or within the timeframe in which contraception is required.